Optimal Revascularization Time in Transient STEMI

Patients admitted with transient ST elevation MI and later normalize completely (symptimos disappear before being treated) are those we normally say are “undergoing a non-ST elevation MI”. This is complex, because revascularization time remains nuclear, as is whether to treat them as STEMI or non-STEMI patients.

The aim of this study was to determine the effects of an immediate strategy, compared against a differed strategy, quantifying infarct size with cardiac magnetic resonance.

 

The study randomized 142 patients with transient ST elevation MI to immediate (as if it were primary PCI in persistent STEMI patients) mean 0.3 hours vs. invasive differed strategy (as non-STEMI patients) with mean 22.7 hours.



Read also: The Ten Commandments for the Fourth Universal Definition of Infarction.


Infarction size measured by CMR at day 4 after the event was small and similar between strategies.

 

Neither were there differences in terms of major cardiac events, a combination of death, reinfarction or revascularization at 30 days (2.9% vs. 2.8%, p=1.00).


Read also: Are Aortic Stenosis and Kidney Dysfunction Associated?


Only 4 patients in the deferred group (5.6%) required emergency intervention given their signs and symptoms while waiting the angiography.

 

Conclusion

Globally, infarct size in patients presenting transient ST elevation MI is small and revascularization strategy, whether immediate or differed, has no influence. Hard events at short term were low and similar between the groups.

 

Original title: Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial.

Reference: Jorrit S. Lemkes et al. European Heart Journal (2019) 40, 283–291.

 

Infarto-elevacion-transitoria-st


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...